Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Novopharm Biotech cleared for phase I trials of melanoma immunotherapy

Oct. 30, 1997

Antitumor activity of LC-9018 correlated with cytokine production

Oct. 28, 1997

KRN-7000 for the treatment of liver metastasis

Oct. 23, 1997

Imutec's Virulizin approved in Mexico for malignant melanoma

Oct. 23, 1997

Update on development of NeoPharm's novel chimeric human protein

Oct. 21, 1997

Bexxar compared to unlabeled MAb in patients with non-Hodgkin's lymphoma

Oct. 21, 1997

Avax evaluates its ovarian cancer vaccine in phase II

Oct. 20, 1997

New GVAX cancer vaccine begins human testing

Oct. 17, 1997

Jenner Technologies initiates clinical testing of AdjuVax-100a

Oct. 16, 1997

Meeting of Biological Response Modifiers Advisory Committee this week

Oct. 14, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...